Speakers
Ana Filipa Alexandre, Global Director, Health Economics Outcomes Research, Astellas Pharma
Abdulrahman AlMesnid, Health Economic Evaluation Lead, Ministry of Health
John Alter, VP, Patient and Health Impact Lead, Hospital Business Unit, Pfizer
Ines Alves, President, ANDO Portugal
Luigi Angelillo, Associate Director, HEOR & New Products Market Access (EMEA), Santen GmbH
Glenn Anley, Global Director Pricing & Access - Covid Therapeutics, GSK
Ad Antonisse, Director Market Access & External Affairs, AstraZeneca BV
Marnix Artz, Head of Patient Access, Pricing & Public Affairs, Netherlands, Merck Group
Dragana Atanasijevic, Head of HTA Department, Institute of Public Health of Serbia
Nico Bacharidis, Founder, growpal
Alex Bastian, Vice President, Value And Market Access, Galapagos NV
Tomer Ben Zaken, Pricing And Alliance Manager, Takeda
Jennifer Cain Birkmose, Vice President, Global Head Of Patient Access And Community Engagement, Swedish Orphan Biovitrum
Jesper Bjerggren, European Market Access Lead Respiratory/Digital Health, Teva Pharmaceuticals
Maria Alejandra Blanc, Director - Regulatory Affairs – Region South, Abbvie
Nadia Bodkin, OLM DEI Expert, Rare Advocacy Movement
Axel Boehnke, Director Market Access EU North, PTC Therapeutics
Luc Boileau, Chief Executive Officer, INESSS
Amanda Bok, CEO, European Haemophilia Consortium
Thomas Bols, Head of Government Affairs and Public Policy, EMEA & APAC, PTC Therapeutics
Vidya Breeveld, Head Public affairs & Market Access, Sanofi
Line Brøns, Senior health economist, Amgros I/S
Hassan Bruneo, Head of Market Access, Pricing & Policy, Canada/Europe/MEA, Alnylam Pharmaceuticals
Anna Bucsics, Project Advisor, Mechanism of Coordinated Access to orphan medicinal products (MoCA)
Nicki Catterick, VP, Head of Global Market Access & Pricing | Neurology & Immunology, Merck Group
Sandro Cesaro-Tadic, Head Strategic Product Pricing, Roche
Lung-I Cheng, Head of Global Value & Access, Cell Therapies, Oncology Business Unit, Takeda
Helene Chevrou-Severac, HEOR RWE Centre of Excellence Head, International & Japan, Alexion
José Luis Sánchez Chorro, Associate Director Market Access Spain, GW Pharmaceuticals
Ali Ciger, Commercial Director, Pain, Pfizer
Francesca Cook, Vice President, Pricing and Marketing Access, RegenxBio
Margarida Costa, Global Pricing & Market Access Manager, Galderma
Warren Cowell, Director Market Access UK, Shionogi Ltd
Sarah Creviston, Vice President, Global Patient Advocacy & Government Affairs, Novartis Gene Therapies
Mike Crosher, Managing Director, Chugai Pharma UK
Charles-Etienne de Cidrac, Director Of Health Insurance, AXA
Carla Deakin, Programme Director - Commercial And Managed Access, NICE
Gilles Ducorroy, Global Head of RWE Services, Novartis
Dominik Dziurda, Head Of Health Services Division, AOTMiT
Michael Ermisch, Specialist, Department Of Pharmaceuticals, G.K.V. Spitzenverband
Gina Ewy, Head of Global Market Access, Hansa Biopharma
Jonathan Galduf, Director Market Access and Public Affairs (Iberia), CSL Behring
Benjamin Gannon, Head of Int’l Access & Policy, Guardant Health
Philippe Ghyssels, VP, Corporate and Global Public Affairs, Ipsen
Ramiro Gilardino, Head, Value & Access Communications, Healthcare Consultancy Group
Christoph Glatzer, Head of Global Market Access, Pricing, RWE, PRO, Johnson & Johnson
Josie Godfrey, Co-Founder and CEO, Realise Advocacy
Wim Goettsch, Special Hta-Advisor, Zorginstituut
Sylvie Greneche, Global Head of Market Access, General Medicines, Sanofi
Marcus Guardian, Chief Operating Officer, EUnetHTA
Laura Guarga, Consultant of Pharmacoeconomic Department, CatSalut
Diego Guarin, Executive Director, Regional Market Access Latin America, Global Market Access, Merck
Josep Maria Guiu Segura, Head of Pharmacy, Pharmacy and Medicines Area, Consorci De Salut I Social De Catalunya
Sanjay Gupta, Vice President, Head of Global RWE & US HEOR, Eisai
Clare Hague, Therapy Area Market Access Lead, Hematology, Janssen Pharmaceuticals
Thomas Hasmann, Vice President, Head of Market Access, Kyowa Kirin International
Tanja Heidbrede, Head RWE Central EU, UCB
Ramon Hernandez Vecino, Global Head of Development Real World Evidence, Sanofi
Phillip Hivale, Head of US Market Access and Value Communications, Healthcare Consultancy Group
Birgit Holz, Global Head of Contracting Innovation, Sanofi
Bill Hu, Professor of Finance, Arkansas State University
Wills Hughes-Wilson, Chief Patient Access & Commercial Planning, Mereo Biopharma
Dawn Ireland, President, CDH International
Shrividya Iyer, Executive Director, Global RWE & US HEOR, Eisai
Daniel Jackson, Global Head of Market Access Policy, UCB
Ulrike Jacobi, Head Of External Affairs And Market Access, Amgen
Saira Jan, Vice-President & Chief Pharmacy Officer, Blue Cross Blue Shield of New Jersey
Yonghua Jing, Director, Real World Evidence & Analytics, Health Economics & Outcomes Research, AbbVie
Elizabeth Johnson, Co-founder, National Association of Medication Access & Patient Advocacy
Navin Joshi, Head of Pricing & Market Access, GlaxoSmithKline
Marcela Junqueira, Oncology Market Access Director - Latin America, Janssen Pharmaceutical
Madhusudan Kabra, Director, Evidence Generation, Otsuka Pharmaceutical
Gomathi Kaliappan, Health Systems Strategy Leader - Global Access, Roche
Lisette Kaskens, Senior Global Market Access Manager, Advanced Accelerator Applications
Alison Keetley, Head of Market Access South East Asia, Johnson & Johnson
Sigrid Klaar, Medical advisor, The Dental and Pharmaceutical Benefits Agency T.L.V.
Jelle Kleijn, Global Head of Acanthamoeba Keratitis, SIFI
Jolanda Koenders, Head Of Patient Value And Access, Takeda
Adam Kundzewicz, Global Head of Tech Partnerships, Boehringer Ingelheim
Diane Langenbacher, Partner, Kautz5 gUG
GAEL LE ROUZO, Global Market Access Director, Eusa Pharma
Jost Leemhuis, Head Of Safety Science, Roche
Giovanny Leon, Pricing & Access Regional Director - LatAm & Canada, Novartis AG
Friedhelm Leverkus, Director Health Technology Assessment And Outcomes Research, Pfizer
Gavin Lewis, Global Head of Market Access, Amgen
Nanxin (Nick) Li, Global/US Market Access Lead, uniQure
Edmund Lim, Executive Director, We CARE Journey
Sara Lopes, Senior Director, Global Market Access & Pricing Governance, Shionogi BV
Catarina Lopes Pereira, Global Market Access Manager, Medac
Elena Lungu, Manager of Policy Development, Patented Medicine Prices Review Board, Government of Canada
Joerg Mahlich, Market Access and Government Affairs Lead, Miltenyi Biomedicine GmbH
Marco Marchetti, Director Of The National Center For Health Technology Assessment, Istituto Superiore di Sanita
Canter Martin, EVP and Managing Director, Healthcare Consultancy Group
Suzanne Mcgurn, President and CEO, CADTH
Erin Mistry, SVP, Head of Payer Strategy, Gov’t Affairs and Trade Relations, CorMedix Inc
Vladimir Mladov, HTA Manager, BIOCAD
Suzanne Morgan, Director, Patient Access Services and National Accounts, NS Pharma, Inc.
Paolo Morgese, EU Director Market Access & Member Relations, Alliance for Regenerative Medicine
Thomas Mueller, Head Of Directorate General 1 - Drugs, Medical Devices, Biotechnology, Federal Ministry of Health Germany
Michael Muller, Head Of Market Access, Western Europe, Sun Pharma
Diane Munch, Head of Global Pricing, Patient & Health Impact, Pfizer
Bogdan Muresan, Associate Director Global HEOR, Teva Pharmaceutical Europe
Nuriya Musina, Head Of Development, Federal State Budgetary Institution, The Center For Healthcare Quality Assessme, Ministry of Health Russian Federation
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Claudia Neuber, Head of Global Pricing, AstraZeneca
Enkeleida Nikai, Head Of Real World Evidence, Senior Director At Janssen Europe, Middle East And Africa (Emea), Janssen Pharmaceutical
Declan Noone, President, European Haemophilia Consortium
Laura O'Hanlon, Director, Hereditary Cancer - International, Myriad genetics
Melvin Olson, Global Head IE Strategy and Innovation, NOVARTIS
Robert Orzechowski, Chief Operating Officer, Lancaster Cancer Centre
Mario Ouwens, Group Director Medical & Payer Evidence Statistics, AstraZeneca
Melissa Paige, Associate Director, Payer/Market Access Marketing, NS Pharma, Inc.
Elena Panitti, Global Head Real World Evidence Excellence, Novartis
Julien Patris, Director Market Access & Policy – Europe / Canada / MEA (CEMEA), Alnylam
Ajinkya Pawar, Director, Real World Investigator, Dupilumab | Respiratory, Sanofi
Mitchell Payne, Global Head, Value and Access Excellence, Novartis Oncology
Marco Penske, Head Of Market Access And Health Care Affairs, Boehringer-Ingelheim
Diogo Teixeira Pereira, Policy Analyst - Office for International Relations and Development, Infarmed
Ed Pezalla, Former Vice President, National Medical Director For Pharmaceutical Policy And Strategy, Aetna; a CVS Pharmacy Health Company
Andres Pichon Riviere, Executive Director And Director Of Health Technology Assessment And Economic Evaluations, I.E.C.S.
Diogo Piedade, Market Access Manager, Medicines for Europe
Carme Pinyol, Head Of Pricing And Market Access Southern Europe, Pierre Fabre
Lara Pippo, Head Of Market Access, Italy, CSL Behring
Ana Plata, Global Head of Pricing, UCB
Mary Lynne Van Poelgeest-Pomfret, President, President of the World Federation for Incontinence and Pelvic Pain - WFIP
Angelina Irizari Policarpio, Head of U.S. HEOR and RWE Communications Team (Market Access), Eisai
Sreeram Ramagopalan, Global Head Real-World Evidence (Market Access), Roche
Andrea Rappagliosi, Vice President Market Access, Public Affairs & Communication EMEA, Canada and LATAM, Edwards Lifesciences
Marco Rauland, Vice President Global Market Access & Pricing - Strategic Planning, Merck Group
Laurene Redding, Head, Value, Access & Policy, Canada, BeiGene
Vijay Reddy, Senior Director - Global Market Access Strategy - Biologics, Biocon Biologics
Trevor Richter, Director Access and Reimbursement, Canada, Gilead Sciences
Kevin Rieger, Head Of Public And Governmental Affairs Dach, Ipsen Pharma Gmbh
Andre Roeder, Head Global Market Access, TETEC AG
Juan Roman, Vice President, Global Market Access, HEOR and Pricing, Krystal Biotech
Igor Rudychev, Vice President, Enterprise Analytics, Horizon Therapeutics
Alric Ruether, Head, International Affairs, IQWiG
Sandrine Ruiz, Global Pricing & Market Access Director, AstraZeneca
Claus Runge, Global Head of Market Access, Public Affairs & Sustainability, Bayer
Marika Russo, Market Access Director, Region Europe, NOVARTIS
Marcelo Sal, Head of Market Access and Pricing, South Cone of South America, PTC Therapeutics
Steve Sandor, Vice President, Market Access And Trade, Paratek Pharmaceuticals , Inc.
Gustavo Saraiva Dos Anjos, Global Payer Strategy Director, Biologics, GlaxoSmithKline
Michael Schroter, Co-Head Sustainable Healthcare Equity, HSBC
Michael Seewald, VP, Global Evidence, Medical BioPharmaceuticals, AstraZeneca
Ayman Semaan, Head of Market Access, Biologix
Maja Sercic, Policy & Science Manager, Medicines for Europe
Jonas Sertorio, Innovation and HTA Consultant, Ministry of Health - Brazil
Raja Shankar, Innovation Lead, AI-Led Strategic Transformation, IQVIA
Rita Shorjian, Business Unit Director – Gulf Countries, Specialty, HCV & Oncology, Abbvie
Tamir Singer, Head of Commercial Development, NHS England
Matt Slabbert, Global Lead – Public Affairs, Cell & Gene Therapy, Bayer
Valeriia Sokolova, Health Economics Manager, BIOCAD
Lotte Steuten, Vice President And Head Of Consulting, Office of Health Economics
Pernille Storm, Head of Global Pricing, H. Lundbeck A/S
Teddy Sun, Senior Manager, Value Strategy & Payer Engagement, Novo Nordisk
Monika Szkultecka-Debek, Vice President, Qualitas Vitae Institute Foundation
Giovanni Tafuri, Director, International Pricing & Reimbursement and Policy Strategy, Apellis Pharmaceuticals
Francesca Tavella, Global payer analytics lead, AstraZeneca
Sam Taylor, Emerging Markets Strategic Pricing Lead, Pfizer
Kris Thiruvillakkat, Sr Director, Global Evidence Market Access Pricing, CSL Behring
Gwilym Thompson, Group Director Worldwide Health Economics and Outcomes Research, Markets (ROW), BMS
Daria Tolkacheva, Head of Health Technology Assessment, JSC BIOCAD
Jörg Tomeczkowski, Associate Director, Global HTA Decision Support, Janssen
Ly Tran, Deputy Secretary, Scientific Advisory Council (Medicines Committee), Zorginstituut
Sheela Upadhyaya, Accelerated Access Collaborative Relationship & Delivery Lead & HST Specialist, National Institute for Health and Care Excellence
Andreas Uttenweiler, Head Patient Value Access & Public Affairs, Takeda Pharma AG
Inneke Van De Vijver, Strategic Advisor - Reimbursement Pharmaceuticals, R.I.Z.I.V. I.N.A.M.I. National Health Insurance Agency
Erik Van Den Berg, Chief Executive Officer, A.M. Pharma
Bart Van Den Daele, Head of External Affairs – Director Market Access - Belux, Gilead Sciences
Goedele Van Haasteren, Staff Member, Swiss Federal Office of Public Health
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Medical Advisor, CZ
Kärt Veliste, Chief Specialist at Department of Medicines and Medical Devices, Haigekassa Estonia
Mihaela Veringa, Senior Manager Global Access Policy & Govt. Affairs, Sobi
Chris Wasden, Head of HappifyDTx, HAPPIFY HEALTH
David Watson, Executive Director, Economic, Health and Commercial Policy, ABPI
Keith White, Head, Global Market Access, Amylyx Pharmaceuticals
Anne Willemsen, Senior Project Manager, Zorginstituut Nederland / EUnetHTA
Scott Williams, Head, Global Public Affairs Rare Diseases and Rare Blood Disorders, Sanofi Genzyme
Leung-Ming Yu, Senior Advisor, HTA and reimbursement, Norwegian Medicines Agency
Natasa Zibelnik, Global Head of Value, Access and Pricing, Eusa Pharma
Fabrizio Zucca, Director Market Access DACH, Alnylam Pharmaceuticals
Get Involved
Connect
|
To Sponsor Or Exhibit
|
To Speak
|
Organiser
